The myasthenia gravis treatment market is anticipated to grow at a CAGR of 7.14% from US$1.973 billion in 2025 to US$2.785 ...

As a result, the muscles become weak when a person performs repeated physical movements. The disease is neither contagious nor inherited but it is often misunderstood as a psychological issue or ...

Cancer of the thymus gland is rare. Most cancers that start in the ... Up to 50 out of 100 people with thymoma (50%) have symptoms of myasthenia gravis (MG). MG is a rare condition that affects the ...

Antozzi C, Vu T, Ramchandren S, et al. Long-term safety and efficacy of nipocalimab in generalized myasthenia gravis: Vivacity-MG3 open-label extension phase results. Neurology. 2025;104(7 suppl 1 ...

Highlights in myasthenia gravis (MG) from the American Academy of Neurology 2025 Annual Meeting include new therapy trials and practice reviews, as discussed by Dr Nicholas Silvestri of the ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis. The Food and Drug Administration (FDA) has approved Imaavy ...

Myasthenia gravis is termed a rare disease, but several pharma companies are battling for the market of more than 70,000 Americans with the neurological disorder. Titled “Imagine Your Zillions ...

The US Food and Drug Administration (FDA) has approved nipocalimab-aahu (Imaavy, Johnson & Johnson) for the treatment of generalized myasthenia gravis (gMG) in adults and adolescents 12 years of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Imaavy plus standard of care led to improvements at ...